Analysis of env Sequence Evolution in Human Immunodeficiency Virus-Infected Patients Receiving Therapy with Nonnucleoside Reverse-Transcriptase Inhibitors

Nonnucleoside reverse-transcriptase inhibitors (NNRTIs) can rapidly select for drug-resistant human immunodeficiency virus type 1 (HIV-1) variants, although their effect on HIV-1 quasi-species diversity is unknown. To determine if changes in env gene diversification occur with NNRTI therapy, we used...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2000-07, Vol.182 (1), p.316-320
Main Authors: Dykes, C., Mootsikapun, P., Dexter, A., Berrios, L., Chiulli, M., Reichman, R. C., Demeter, L. M.
Format: Article
Language:English
Subjects:
AIDS/HIV
Antiretrovirals
Biological and medical sciences
Concise Communications
DNA
Drug Resistance, Microbial
env gene
Evolution
Evolution, Molecular
Genes, Viral
Heteroduplex Analysis
HIV 1
HIV Envelope Protein gp120 - genetics
HIV Infections - drug therapy
HIV Infections - genetics
HIV Infections - virology
HIV-1 - drug effects
HIV-1 - genetics
Human immunodeficiency virus 1
Human viral diseases
Humans
Infectious diseases
Medical sciences
Polymerase chain reaction
Protease inhibitors
Reverse transcriptase inhibitors
Reverse Transcriptase Inhibitors - pharmacology
Sequence Analysis
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Viruses
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nonnucleoside reverse-transcriptase inhibitors (NNRTIs) can rapidly select for drug-resistant human immunodeficiency virus type 1 (HIV-1) variants, although their effect on HIV-1 quasi-species diversity is unknown. To determine if changes in env gene diversification occur with NNRTI therapy, we used the heteroduplex tracking assay (HTA) to study HIV-1 env sequence diversity in 2 groups of patients: those who were on no therapy or were on chronic antiretroviral therapy and those who had just initiated NNRTIs. Forty-nine paired samples from 46 patients were analyzed. Fourteen of 32 paired samples from the NNRTI group and 9 of 17 paired samples from the control group had HTA changes (P > .10). There was no correlation between HTA change and sampling time interval, baseline virus load, change in virus load, or development of NNRTI resistance. Thus, we found no significant correlation of NNRTI therapy with changes in env HTA patterns, suggesting that these treatments had little short-term impact on HIV-1 quasi-species diversity.
ISSN:0022-1899
1537-6613
DOI:10.1086/315691